|
Current issue
Archive
Manuscripts accepted
About the journal
Editorial board
Abstracting and indexing
Contact
Instructions for authors
Ethical standards and procedures
Editorial System
Submit your Manuscript
 
|
2/2023
vol. 98 abstract:
Review paper
Proton pump inhibitors – their possible influence on the development of small intestine bacterial overgrowth in children
Zuzanna Wasielewska
1
,
Aneta Krogulska
1
,
Anna Szaflarska-Popławska
2
Pediatr Pol 2023; 98 (2): 154-160
Online publish date: 2023/06/19
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
Proton pump inhibitors (PPIs) are safe drugs that have been commonly used for many years by both general practitioners and specialists. They are widely used in the paediatric population, mainly in the treatment of gastroesophageal reflux disease, but also for oesophagitis, gastritis and/or duodenitis. Proton pump inhibitors use increases the pH of the stomach, which disrupts the physiological defensive barrier and may lead to the development of an abnormal microbiome in the further parts of the digestive tract, resulting in small intestinal bacterial overgrowth (SIBO) and symptoms such as diarrhoea, production of gas, nonspecific abdominal pain, flatulence, lack of growth or weight loss, protein or energy malnutrition, and vitamin A, D, K and B12 deficiency. The study analyses the influence of combining PPIs with probiotics or prokinetics on the chance of SIBO developing in children. There are currently no diagnostic standards or therapeutic guidelines for children diagnosed with SIBO.
keywords:
children, proton pump inhibitors, small intestinal bacterial overgrowth, gut microbiome, small intestine bacterial overgrowth |
POLSKI
